pcn poster

Posters

Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to Selective Serotonin Reuptake Inhibitors: The VIVRE Study

This study assessed the efficacy of vortioxetine versus desvenlafaxine in patients with MDD experiencing partial response to treatment with an SSRI. Vortioxetine was noninferior to desven...

Michael Adair , MBChB;

10/26/2023

Equivalent Antidepressant Outcomes with Esketamine in TMS Non-Responders

Both Transcranial Magnetic Stimulation (TMS) and Esketamine are FDA approved therapies for patients with Major Depressive Disorder who have failed at least one conventional antidepressant...

Tobias F. Marton , MD, PhD;

10/26/2023

Esketamine Nasal Spray Improves Functioning in Patients with Treatment Resistant Depression: Results from ESCAPE‑TRD

This analysis evaluated changes in functioning and productivity in patients with treatment resistant depression who received either esketamine nasal spray or quetiapine extended release, ...

Hannah Bowrey , PhD;

10/26/2023

Efficacy of Brexpiprazole in Patients With Agitation Associated With Alzheimer’s Dementia Analyzed by Presence or Absence of Psychosis: a Pooled Analysis

This post hoc analysis explored the efficacy of brexpiprazole 2 or 3 mg/day in patients with agitation associated with Alzheimer’s dementia, based on presence or absence of psychosis at b...

Anja Farovik , PhD;

10/26/2023

Efficacy of Fremanezumab in Reducing Depression in Patients With Migraine and Major Depressive Disorder: Results of the UNITE Study

Depression is a prevalent comorbidity associated with migraine. In patients with migraine and major depressive disorder, treatment with fremanezumab was associated with significant reduct...

Richard Lipton , MD;

10/26/2023

Efficacy of Long-acting Injectable Risperidone in Acute and Stable Patients with Schizophrenia: Prior Anti-Psychotic Use, and Relapse

Adult patients with acute or stable schizophrenia received RBP-7000 (a once-monthly subcutaneous extended-release risperidone formulation) in two Phase III studies (8-week inpatient doubl...

Andrea Wilson , PharmD, BCPS, PhD;

10/26/2023

Efficacy of Lumateperone in Pooled Short-Term Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar II Disorder

This post hoc, pooled analysis of 3 short-term, placebo-controlled studies evaluated the efficacy of once-daily lumateperone 42mg monotherapy and adjunctive therapy in patients experienci...

William Rowe , MSN, RN, ACNP, BC;

10/26/2023

Emotion Regulation Across Psychiatric Disorders: A Systematic Review and Meta-analysis

A systematic review and meta-analysis exploring the magnitude of emotion dysregulation in individuals with various diagnosed psychiatric conditions compared to healthy individuals. Using ...

Jordan Stellern , BS;

10/26/2023

EMPOWERing the Next-Generation: A phase 2 Program to Evaluate Emraclidine, a Selective M4 Positive Allosteric Modulator (PAM), for the Treatment of Schizophrenia

Detailed study designs for the EMPOWER program will be presented. Primary outcome measure for EMPOWER 1 and 2 is change from baseline in PANSS total score at week 6. Other outcome measure...

Koji Takahashi , PhD;

10/26/2023

Enhancing Access to Mental Health Services: The Growing Use of Telemedicine Among Physician Assistants/Associates in Psychiatry

Challenges to accessing affordable and high-quality mental health care persist amidst significantly rising demand. This study explored the use of telemedicine technology among PAs practic...

Mirela Bruza-Augatis , MS, PA-C;

10/26/2023

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products